VLA15 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lyme Borreliosis
Conditions
Lyme Borreliosis
Trial Timeline
Jul 1, 2019 → Mar 28, 2022
NCT ID
NCT03970733About VLA15 + Placebo
VLA15 + Placebo is a phase 2 stage product being developed by Pfizer for Lyme Borreliosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03970733. Target conditions include Lyme Borreliosis.
What happened to similar drugs?
0 of 3 similar drugs in Lyme Borreliosis were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07226882 | Phase 3 | Recruiting |
| NCT04801420 | Phase 2 | Completed |
| NCT03970733 | Phase 2 | Completed |
| NCT03769194 | Phase 2 | Completed |
Competing Products
8 competing products in Lyme Borreliosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1975 | Moderna | Phase 2 | 0 |
| VLA15 with Alum + VLA15 without Alum | Pfizer | Phase 1 | 29 |
| VLA15 + Placebo | Pfizer | Phase 2 | 35 |
| VLA15 + Placebo | Pfizer | Phase 3 | 47 |
| VLA15 + Placebo | Pfizer | Phase 2 | 35 |
| VLA15 | Pfizer | Phase 3 | 44 |
| VLA15 | Pfizer | Phase 3 | 40 |
| Multivalent recombinant OspA Lyme Borreliosis Vaccine + Multivalent recombinant OspA Lyme Borreliosis Vaccine + Multivalent recombinant OspA Lyme Borreliosis Vaccine | Baxter | Phase 1/2 | 29 |